Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A company is trying to unlock a key to aging, in a long-overlooked body part - 2Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential
- 321 Things You Ought to Never Share with Your Childless Companion
- 4The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- 5The Significance of a Land Lawyer for Your Business
- Geminid meteor shower, one of the year's most reliable, peaks this weekend
- We tasted one of the 10,000 Hershey's Dubai chocolate bars being resold on eBay. Is it worth the hype?
- How HIV/AIDS got its name − the words Americans used for the crisis were steeped in science, stigma and religious language
- Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- Best Quest for new employment Site for You to Track down Amazing open doors
- Vote in favor of the juice that you love for its medical advantages!
- Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
